Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-10-03
2006-10-03
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093200, C435S069100, C435S320100, C435S325000, C435S455000, C514S04400A
Reexamination Certificate
active
07115258
ABSTRACT:
The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. Methods and compositions for carrying out such gene transfer and grafting are described.
REFERENCES:
patent: 4419446 (1983-12-01), Howley et al.
patent: 4663349 (1987-05-01), Repta
patent: 4758571 (1988-07-01), Curtius et al.
patent: 4771073 (1988-09-01), Repta
patent: 4826875 (1989-05-01), Cheisi
patent: 4863962 (1989-09-01), Karoum et al.
patent: 4873263 (1989-10-01), Repta
patent: 4970200 (1990-11-01), Birkmayer et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5112861 (1992-05-01), Backstrom et al.
patent: 5135956 (1992-08-01), Borg et al.
patent: 5206226 (1993-04-01), Sabin
patent: 5210076 (1993-05-01), Berliner et al.
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 5576353 (1996-11-01), Youdim et al.
patent: 5587378 (1996-12-01), Suzuki et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5624820 (1997-04-01), Cooper
patent: 5650443 (1997-07-01), Johnson et al.
patent: 5658900 (1997-08-01), Boireau et al.
patent: 5674703 (1997-10-01), Woo et al.
patent: 5674885 (1997-10-01), Boireau et al.
patent: 5677344 (1997-10-01), Greenfield et al.
patent: 5686423 (1997-11-01), Wang et al.
patent: 5703100 (1997-12-01), McDonald et al.
patent: 5712270 (1998-01-01), Sabb
patent: 5756548 (1998-05-01), Flitter et al.
patent: 5756550 (1998-05-01), Johnson et al.
patent: 5807871 (1998-09-01), Moltzen et al.
patent: 5817491 (1998-10-01), Yee et al.
patent: 5817690 (1998-10-01), Mewshaw
patent: 5817699 (1998-10-01), Flores et al.
patent: 6103226 (2000-08-01), Kang et al.
patent: 6506378 (2003-01-01), Kang
patent: 0123456 (2000-01-01), None
Juengst BMJ, 326:1410-11, 2003.
Rosenberg et al, Science 287:1751, 2000.
Friedmann, Science 287(5461):2163-5, 2000.
Verma et al Nature 389:239-242, 1997.
Touchette, Nat. Med. 2(1) 7-8, 1996.
Howard Nat Biotech 21:1117-1118, 2003.
Bankiewicz et al. Experimental Neurology, 144:147-I56, 1997.
Bjorklund et al Nature Neuroscience, 3:537-544, 2000.
Burton et al Gene Therapy 10:1721-177, 2003.
Erickson et al PNAS 93:5166-5171, 1996.
Nirenberg et al J. Neurosci, 16:4135-4145, 1996.
Check Nature 422:7, 2003.
Lee et al, Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. J Neurosci. 19(8):3266-74, 1999.
Eck et al., “Gene-based therapy.” Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill-Nith Edition: 77-101, 1996.
Raymon et al., “Application of ex Vivo Gene Therapy in the Treatment of Parkinson's Disease.” Exp. Neurology, vol. 144 : 82-91, 1997.
Horellou et al., “Gene Therapy for Parkinson's Disease.” Molecular Neurobiol., vol. 15: 241-256, 1997.
Bankiewicz et al., “Practical Aspects of the Development of ex Vivo and in Vivo Gene Therapy for Parkinson's Disease.” Exp. Neurology, vol. 144: 147-156, 1997.
Sanberg et al., “Cellular therapeutic approaches for neurodegenerative disorders.” Proceedings of the 1998 Miami Bio/Tech. Winter Symposium, Nucleic acids symposium series No. 38, pp. 139-142, Feb. 1998.
Scheffler et al., “Marrow-mindedness : a perspective on neuropoiesis.” TINS, vol. 22 (8): 348-357, 1999.
Orkin et al., “Report and recommendations of the panel to assess the NIH investment in research on gene theapy.” pp. 1-20, Dec. 1995.
Bartlett et al., “Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters,”Proc. Natl. Acad. Sci. USA, 93:8852-8857, 1996.
Bencsics et al., “Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts,”J. Neurosci. 16, 4449 1996.
Bjorklund and Stenevi, “Intracerebral neural grafting: a historical perspective,” in Neural Grafting on the Mammalian CNS, Bjorklund and Stenevi, eds, Amsterdam: Elservier, 3-11, 1985.
Brundin et al., “Intracerebral grafts of neuronal cell suspensions,” in Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 6, pp. 51-60, 1985.
Caettano and MacKay, “Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor,”Nature347:762-765, 1990.
Chang et al., “Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions,”Neuroscience, 88, 2 617-628, 1999.
Cooper et al., “L-Dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice,”J. Pharm. Pharmacol. 39:809-818, 1987.
Das, “Intraparenchymal transplantation,” in Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 3 pp. 23-30 1985.
David and Aguayo, “Peripheral nerve transplantation techniques to study axonal regeneration from the CNS of adult mammals,” in Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 7, pp. 61-70, 1985.
Erickson and Eiden, “Functional identification and molecular cloning of a human brain vesicle monoamine transporter,”J Neurochem. 61(6):2314-2317, 1993.
Erickson et al., “Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter,”Proc Natl Acad Sci USA. 93(10):5166-71, 1996.
Fisher et al., “Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa,”Neuron6:371-380, 1991.
Fisher, et al., “Transduction with recombinant adeno-virus for gene therapy is limited by leading-strand synthesis,”J. Virol., 70(1):520-532, 1996.
Freed, “Transplantation of tissues to the cerebral ventricles: methodological details and rate of graft survival,” in Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 4, pp. 31-40, 1985.
Furukawa et al., “GTP-cyclohydrolase I gene mutations in hereditary progressive and dopa-responsive dystonia,”Ann. Neurol. 39, 609-617, 1996.
Gasnier et al, “Expression of a bovine vesicular monoamine transporter in COS cells,”FEBS Lett. 342, 225 1994.
Hattori et al., “Dendro axionic neurotransmission. II Morphological sites for the synthesis, binding and release of neurotransmitters in dopaminergic dendrites in the substantia nigra and cholinergic dendrites in the neostriatum,”Brain Res. 170:71-83, 1979.
Horellou et al., “In vivo release of DOPA and dopamine from genetically engineered cells grafted to denervated rat striatum,”Neuron5:393-402, 1990.
Hoshimaru et al., “Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myconcogene,”Proc. Natl. Acad. Sci. USA93, 1518 1996.
Howell et al., “Cloning and functional expression of a tetrabenzine sensitive vesicular monoamine transporter from bovine chromaffin granules,” FEBS Lett. 338(1):16-22, 1994.
Ichinose et al., “Heredity progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene,”Nat. Genet. 8, 236 1994.
Joki, et al., “Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir,”Human Gene Ther., 6:1507-1513, 1995.
Juncos et al., “Levodopa methyl ester treatment of Parkinson's disease,”Neurology37:1742-1245, 1987.
Kang et al., “Regulation of dopamine production by genetically modified primary fibroblasts,”J. Neuro
Arch Development Corp.
Barnes & Thornburg LLP
Kaushal Sumesh
Martin Alice O.
LandOfFree
Vesicular monoamine transporter gene therapy in parkinson's... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vesicular monoamine transporter gene therapy in parkinson's..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vesicular monoamine transporter gene therapy in parkinson's... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3674121